Navigation Links
Pradaxa Bleeding Allegations Lawyer: Resource4thePeople Reports New Study May Produce Treatment to Reverse Anti-Clotting Medication Effects
Date:11/28/2013

San Diego, CA (PRWEB) November 28, 2013

http://www.resource4thepeople.com/defectivedrugs/pradaxa-lawsuits.html

Resource4thePeople announced today its latest consumer update over allegations that the popular blood thinner Pradaxa (dabigatran) may cause irreversible internal bleeding problems.

A recent study funded by the company has produced results that shows scientists are close to finding a method of reversing the effects of the anti-clotting medication, which according to numerous Pradaxa lawsuits* alleging bleeding problems, up to now have been irreversible.

The research was detailed in a Nov. 18 press release** by the drug's manufacturer and detailed in a U.S. News and World Report story*** the same day. The study has not officially been made public because it is preliminary and has not been published in a medical journal yet.

The U.S. News report said "It's easier for patients to take Pradaxa than the older, standard blood thinner warfarin. But unlike warfarin, there's no way to rapidly reverse its action. That can be a life-threatening problem in emergency situations. Doctors have reported cases of patients on Pradaxa who have died after accidents because their blood wouldn't clot."

An independent view of the research and allegations of serious bleeding problems in connection with Pradaxa were contained in the story from a Dutch medical vascular expert who was quoted as saying: "The next step will be actually demonstrating that, for patients who come in with a major bleed with Pradaxa, this does actually improve the outcome."

The inability to reverse the effects of Pradaxa and allegations of bleeding problems are central to the federal lawsuits* from across the country that have been assigned to U.S. District Court Judge David R. Herndon in the Southern District of Illinois. There are now over 1,500 such lawsuits involved.

"We are encouraged by this new research that shows there may be a way of reversing the effects of Pradaxa in order to avoid the life-threatening conditions that are alleged in hundreds of these lawsuits," said Resource4thePeople.

"In the meantime, we will continue to respond to the increased number of inquiries we have been receiving from consumers affected by these allegations by maintaining our policy of offering free consultations about their rights to seek compensation for injuries they may have suffered.

The court file in the multidistrict litigation* includes a summation of the Pradaxa allegations:

“All the actions share common factual questions arising out of allegations that plaintiffs suffered severe bleeding or other injuries as a result of taking the drug Pradaxa (dabigatran etexilate) and that defendants did not adequately warn prescribing physicians of the risks associated with Pradaxa, including the potential for severe or fatal bleeding, and that there is no reversal agent to counteract the Pradaxa’s anticoagulation effects.”

Resource4thePeople also notes an independent, non-profit**** monitoring medical safety on Oct. 17, 2013 posted figures that showed that the FDA received more reports about side effects about Pradaxa than any other drug the FDA monitors.

The Institute for Safe Medical Practices in its QuarterWatch said that 3,292 reports warning of adverse events, including 582 deaths, were filed over Pradaxa (dabigatran) in 2012.

"For a second straight year dabigatran and warfarin are the most frequently named suspect drugs in direct reports to the FDA.," the authors of the report wrote.

"QuarterWatch has reported on the risks of anticoagulants previously and judged them to be one of the most dangerous of all outpatient drug treatments. The same property that allows anticoagulants to reduce the risk of strokes and blood clots elsewhere in the body leads to high risks for hemorrhage and other bleeding. The result is tens of thousands of emergency room visits or hospitalizations each year."

Resource4thePeople also notes that other cases continue to be filed in state courts across the country, including five recent cases***** filed in Illinois where plaintiffs are claiming that relatives either died or suffered serious bleeding problems from the use of Pradaxa.

The Madison-St. Clair Record reported****** Sept. 26, 2013 that "Some of the plaintiffs claim their relatives died within months of taking Pradaxa, while others claim chronic bleeding caused by the drug required them to be given blood transfusions to prevent their deaths."

In another Pradaxa development, the recently published findings of a trial that was conducted to determine whether Pradaxa (dabigatran) is an effective alternative to warfarin in patients with atrial fibrillation was terminated because of a high number of bleeding incidents attributed to Pradaxa.

The results of the study******* were published in the Sept. 1, 2013 edition of the New England Journal of Medicine and involved hundreds of patients with mechanical heart valves who were tested in comparisons of the two popular anticoagulants.

The anticoagulant trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group, according to the published findings.

The researchers reached the following conclusion:

"The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk."

Bloomberg News, in a Dec. 11, 2012 posting, reported******** that Pradaxa “has been linked to more than 500 U.S. deaths over a two-year period.”

Bloomberg also reported that “Concerns about Pradaxa’s safety surfaced soon after U.S. doctors began prescribing it. FDA officials said they received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011."

Sources:
*IN RE: Pradaxa Product Liability Litigation, U.S. District Court, Southern District of Illinois, MDL No. 2385
**http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/18_november_2013dabigatranetexilate.html
***http://health.usnews.com/health-news/news/articles/2013/11/18/antidote-might-reverse-complication-from-blood-thinner-pradaxa
****http://www.ismp.org/QuarterWatch/pdfs/2012Q4.pdf
***** Case #s 13-L-469, 13-L-470, 13-L-467, 13-L-468, 13-L-466, St. Clair County Circuit Court, Ill.
****** http://madisonrecord.com/issues/895-product-liability/259488-five-pradaxa-suits-filed-in-st-clair-county#
******* http://www.nejm.org/doi/full/10.1056/NEJMoa1300615
******** http://www.bloomberg.com/news/2012-12-11/boehringer-sued-by-hundreds-over-bleeding-tied-to-pradaxa.html

Read the full story at http://www.prweb.com/releases/2013/11/prweb11374789.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pradaxa Lawsuits Continue to Mount, With Filing of New Pradaxa Wrongful Death Claim in Pennsylvania by Wright & Schulte LLC
2. Pradaxa Lawsuits Progress, as Bernstein Liebhard LLP Notes Establishment of Bellwether Case Selection Protocol in Federal Pradaxa Bleeding Litigation
3. Pradaxa Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Issuance of New Order in Federal Pradaxa Bleeding Litigation
4. New Data on Pradaxa Bleeding Side Effects Draws Comment from Pradaxa Lawsuit Lawyers at Wright & Schulte LLC
5. DrugRisk Alert: Pradaxa Leads Study of Complication Reports to FDA
6. DrugNews: Court Records Show Growth In Claims Alleging Pradaxa Bleeding Injury
7. Doyle Raizner Attorney Presenting Pradaxa MDL Update at AAJ Seminar
8. DrugNews: Pradaxa Study Reveals Stroke, Bleeding and Heart Attack Risks In Some Patients
9. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Pradaxa Bleeding Litigation
10. Pradaxa Bleeding Lawsuits Help: Resource4thePeople Reports another Medical Research Study Finds Increased Bleeding Risks
11. Pradaxa Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Issuance of New Case Management Order in Federal Pradaxa Bleeding Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
Breaking Medicine Technology: